MedImmune LLC
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 85
- Registration Number
- NCT01769417
- Locations
- ๐บ๐ธ
Research Site, Miami, Florida, United States
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
Phase 2
Completed
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Biological: Anifrolumab
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 218
- Registration Number
- NCT01753193
- Locations
- ๐บ๐ฆ
Research Site, Vinnytsia, Ukraine
A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Mavrilimumab 100 mgBiological: Golimumab 50 mg
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 215
- Registration Number
- NCT01715896
- Locations
- ๐ฌ๐ง
Research Site, Plymouth, United Kingdom
A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Mavrilimumab 100 mg
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 409
- Registration Number
- NCT01712399
- Locations
- ๐ฌ๐ง
Research Site, London, United Kingdom
A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Mavrilimumab 150 mgBiological: Mavrilimumab 100 mgBiological: Mavrilimumab 30 mgOther: Placebo
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 420
- Registration Number
- NCT01706926
- Locations
- ๐บ๐ฆ
Research Site, Vinnytsia, Ukraine
A Phase 1/2 Study to Evaluate MEDI4736
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 1022
- Registration Number
- NCT01693562
- Locations
- ๐ฌ๐ง
Research Site, Sutton, United Kingdom
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Phase 2
Terminated
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Biological: TralokinumabOther: Placebo
- First Posted Date
- 2012-06-27
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 409
- Registration Number
- NCT01629667
- Locations
- ๐ต๐ช
Research Site, Lima, Peru
A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Biological: Tralokinumab 300 mg
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 30
- Registration Number
- NCT01592396
- Locations
- ๐ต๐ฑ
Research Site, ลรณdลบ, Poland
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
Phase 1
Completed
- Conditions
- Multiple Sclerosis, Relapsing Forms
- Interventions
- Drug: MEDI-551 30 MG-IVDrug: MEDI-551 60 MG-SCDrug: MEDI-551 100 MG-IVDrug: MEDI-551 300 MG-SCDrug: MEDI-551 600 MG-IVDrug: PLACEBO-IV-SC
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 56
- Registration Number
- NCT01585766
- Locations
- ๐บ๐ฆ
Research Site, Kyiv, Ukraine
A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Trivalent Influenza Virus VaccineOther: Placebo
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 303
- Registration Number
- NCT01579916
- Locations
- ๐บ๐ธ
Research Site, Portland, Oregon, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath